Tazarotene

DRUG5 trials

Sponsors

UCSF Benioff Children's Hospital Oakland, McGill University, Allergan, Stiefel, a GSK Company

Conditions

Acne VulgarisCutaneous T-Cell LymphomaNeoplastic SyndromeSkin Carcinoma

Phase 1

Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study

McGill UniversityCutaneous T-Cell Lymphoma

Start: 2008-10-31End: 2012-12-31Target: 15Updated: 2008-10-24

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

CompletedNCT01019603

Stiefel, a GSK CompanyAcne Vulgaris

Start: 2009-10-12End: 2009-12-20Updated: 2017-06-23

Phase 2

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face

CompletedNCT00489086

UCSF Benioff Children's Hospital OaklandNeoplastic Syndrome

Start: 2004-07-31End: 2012-06-30Updated: 2020-10-29

Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Chest and Back

CompletedNCT00783965

UCSF Benioff Children's Hospital OaklandSkin Carcinoma

Start: 2004-07-31End: 2014-01-31Updated: 2016-02-11

Phase 4

Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris

CompletedNCT00834210

AllerganAcne Vulgaris

Start: 2008-12-31End: 2009-09-30Updated: 2011-10-31